|
gptkbp:instanceOf
|
antipsychotic medication
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:approvedBy
|
gptkb:United_States
|
|
gptkbp:ATCCode
|
gptkb:N05AX12
|
|
gptkbp:blackBoxWarning
|
suicidal thoughts and behaviors in children, adolescents, and young adults
increased mortality in elderly patients with dementia-related psychosis
|
|
gptkbp:CASNumber
|
129722-12-9
|
|
gptkbp:chemicalFormula
|
C23H27Cl2N3O2
|
|
gptkbp:co-marketedBy
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:drugClass
|
antipsychotic medication
|
|
gptkbp:eliminationHalfLife
|
75 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
gptkb:tablet
oral solution
disintegrating tablet
extended-release injectable suspension
|
|
gptkbp:genericAvailable
|
yes
|
|
gptkbp:genericName
|
gptkb:aripiprazole
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Abilify
|
|
gptkbp:indication
|
gptkb:Tourette's_disorder
bipolar disorder
schizophrenia
irritability associated with autism
major depressive disorder (adjunct)
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Otsuka_Pharmaceutical
|
|
gptkbp:mechanismOfAction
|
antagonist at serotonin 5-HT2A receptors
partial agonist at dopamine D2 receptors
partial agonist at serotonin 5-HT1A receptors
|
|
gptkbp:metabolism
|
liver (CYP2D6, CYP3A4)
|
|
gptkbp:patentExpiryUS
|
2015
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:riskFactor
|
gptkb:orthostatic_hypotension
gptkb:metabolic_syndrome
seizures
neuroleptic malignant syndrome
tardive dyskinesia
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular injection
|
|
gptkbp:sideEffect
|
nausea
vomiting
anxiety
headache
weight gain
restlessness
insomnia
akathisia
|
|
gptkbp:synonym
|
gptkb:aripiprazole
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Otsuka_Pharmaceutical_Co.
gptkb:Otsuka
gptkb:aripiprazole
gptkb:Otsuka_Holdings
|
|
gptkbp:bfsLayer
|
6
|